Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer
BEDFORD, Mass.–December 12, 2017 —Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Alison Lawton as president and chief operating officer. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry.
“Alison is a tremendous addition to the Kaleido team,” said Michael Bonney, chief executive officer and chair of Kaleido. “Her experience in building and leading organizations, combined with her extensive work in developing and commercializing products that address important patient needs will be instrumental as Kaleido enters its next phase of growth.”
Ms. Lawton was most recently chief operating officer at Aura Biosciences, and previously held the same role at OvaScience. Prior to that, she spent more than 20 years in various positions of increasing responsibility at Genzyme Corporation and subsequently as part of Sanofi, following its 2011 acquisition of Genzyme. At Genzyme, Ms. Lawton served as Senior Vice President and General Manager of the company’s biosurgery unit, where she was responsible for global orthopedics, surgical and regenerative medicine businesses, and also oversaw global market access, including regulatory affairs, health outcomes and global policy. Previously, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis. She is a member of the board of directors of ProQR Therapeutics, Verastem Inc., and Magenta Therapeutics. She earned her Bachelor of Science degree in Pharmacology from King’s College London.
“I am thrilled to be joining a company that is poised to revolutionize human health with an innovative approach to harnessing the microbiome,” said Ms. Lawton. “In a short period of time, Kaleido has generated a significant amount of human data based on a unique discovery platform, produced a compelling pipeline in multiple therapeutic areas, and assembled a talented leadership team. I am looking forward to working with the team to realize Kaleido’s exciting potential.”
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome’s natural roles in promoting health. For more information, please visit: http://www.kaleido.com.